Startseite
Märkte
Charts & Ideen
Algo
Nachrichten
Store
Broker
Herunterladen
Wirtschaftskalender
Handelssignale
WebTerminal
Geben Sie
/
ein, um zu suchen: @user, $symbol
Suche
Einloggen
Eröffnen Sie ein Konto
Deutsch
English
Русский
中文
Español
Português
日本語
한국어
Français
Italiano
Türkçe
TGTX
#1199
TG Therapeutics, Inc.
30.0
9
-0.36%
Sektor:
Basis:
Gewinnwährung:
Tagesspanne
Jahresspanne
Tagesänderung
-0.36%
Monatliche Änderung
-2.37%
6 month change
+5.28%
Jahresänderung
+6.33%
Vorheriger Schlusskurs
30.2
0
Open
30.0
9
Bid
Ask
Low
30.0
9
High
30.0
9
Volumen
136
Märkte
Aktien
Gesundheitswesen
TGTX
Open full chart
Financials
Overview
Finanzbericht
Statistics
Dividends
Quarterly
Annual
Value
Q3, 24
Q4, 24
Q1, 25
Q2, 25
Q3, 25
TTM
Key stats
Total common shares outstanding
155.67 M
157.07 M
158.76 M
158.67 M
158.76 M
—
Valuation ratios
Enterprise value
3.45 B
4.55 B
6.13 B
5.58 B
5.66 B
21.92 B
Price to earnings ratio
206.57
200.67
157.72
94.71
12.95
466.05
Price to sales ratio
13.3
14.67
16.12
12.81
11
54.61
Price to cash flow ratio
127.72
119.11
105.32
98.15
83.35
405.93
Price to book ratio
5.09
21.7
7.49
6.27
4.36
39.82
Enterprise value to EBITDA ratio
-8 444.09
108.29
102.35
64.98
55.06
330.68
Profitability ratios
Return on assets %
0.01
0
0.01
0.04
0.38
0.43
Return on equity %
0.02
0.01
0.02
0.1
0.64
0.78
Return on invested capital %
38.64
12.57
14.03
47.45
-294.65
-220.6
Gross margin %
88.86
85.77
87.14
86.58
82.63
342.12
Operating margin %
14.82
10.55
7.13
24.69
18.16
60.52
EBITDA margin %
14.84
27.69
7.14
24.69
18.17
77.7
Net margin %
4.63
1.77
4.19
19.97
241.73
267.66
Liquidity ratios
Quick ratio
3.91
5.03
3.04
2.96
2.89
13.91
Current ratio
4.59
6.25
4.02
3.86
3.82
17.96
Inventory turnover
0.11
0.16
0.12
0.12
0.19
0.58
Asset turnover
0.17
0.19
0.2
0.21
0.19
0.78
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
Long term debt to total assets ratio
0.42
0.42
0.37
0.35
0.24
1.38
Long term debt to total equity ratio
1.27
1.1
1.03
0.89
0.4
3.42
Per share metrics
Operating cash flow per share
0.08
0.16
0.18
-0.05
0.14
0.43
EBIT per share
0.08
0.19
0.05
0.21
0.18
0.64
EBITDA per share
0.08
0.19
0.05
0.21
0.18
0.64
Total debt per share
—
—
—
—
—
—
Cash per share
2.12
1.94
1.7
1.72
1.11
6.46
Net current asset value per share
3.57
3.53
3.96
4.08
3.73
15.3
Tangible book value per share
1.2
1.39
1.46
1.7
3.77
8.32
Working capital per share
2.79
2.97
2.98
3.03
2.75
11.72
Book value per share
1.2
1.39
1.46
1.7
3.77
8.32
Nachrichten
TGTX Q4 Earnings Lag Estimates, Briumvi Sales Drive Top Line
TG Therapeutics (TGTX) Misses Q4 Earnings Estimates
TG: EPS verfehlt Schätzungen um 0,23 $ - Umsatz besser als erwartet
TG earnings missed by $0.23, revenue topped estimates
Geron (GERN) Reports Q4 Loss, Misses Revenue Estimates
TG Therapeutics faces earnings test as Briumvi growth accelerates
TG Therapeutics (TGTX) Earnings Expected to Grow: What to Know Ahead of Q4 Release
BRIUMVI im Fokus: TG Therapeutics stellt Studiendaten auf ACTRIMS-Forum vor
TG Therapeutics presents BRIUMVI data at ACTRIMS forum
TG Therapeutics: B.Riley bestätigt Kaufempfehlung dank starkem Briumvi-Wachstum/n
TG Therapeutics stock maintains Buy rating at B.Riley on strong Briumvi growth
TG Therapeutics stellt neue Daten zu MS-Medikament BRIUMVI auf Fachkongress vor